Curis, Inc. Announces Genentech, Inc.'s Expected Initiation of Pivotal Phase II Trial in Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitor

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech has indicated that it expects to initiate in January 2009 a pivotal Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with metastatic or locally advanced basal cell carcinoma (BCC). Under the companies’ collaboration agreement, Curis will receive a $6 million cash payment from Genentech following initiation of this pivotal trial.

Back to news